Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer.

Hirano T, Yasuda H, Hamamoto J, Nukaga S, Masuzawa K, Kawada I, Naoki K, Niimi T, Mimasu S, Sakagami H, Soejima K, Betsuyaku T.

Mol Cancer Ther. 2018 Feb 21. pii: molcanther.1033.2017. doi: 10.1158/1535-7163.MCT-17-1033. [Epub ahead of print]

PMID:
29467275
2.

Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, Naoki K, Soejima K, Betsuyaku T.

Oncotarget. 2017 Nov 6;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 1.

3.

Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors.

Hamamoto J, Yasuda H, Aizawa K, Nishino M, Nukaga S, Hirano T, Kawada I, Naoki K, Betsuyaku T, Soejima K.

Oncol Lett. 2017 Sep;14(3):3559-3565. doi: 10.3892/ol.2017.6591. Epub 2017 Jul 18.

4.

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.

Nukaga S, Yasuda H, Tsuchihara K, Hamamoto J, Masuzawa K, Kawada I, Naoki K, Matsumoto S, Mimaki S, Ikemura S, Goto K, Betsuyaku T, Soejima K.

Cancer Res. 2017 Apr 15;77(8):2078-2089. doi: 10.1158/0008-5472.CAN-16-2359. Epub 2017 Feb 15.

PMID:
28202511
5.

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.

Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.

Mol Cancer Res. 2017 Jan;15(1):106-114. doi: 10.1158/1541-7786.MCR-16-0211. Epub 2016 Oct 5.

6.
7.

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer.

Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.

Oncotarget. 2015 Nov 17;6(36):38789-803. doi: 10.18632/oncotarget.5887.

8.

Blue-Black Trachea as a Result of Minocycline-induced Hyperpigmentation.

Asakura T, Nukaga S, Namkoong H, Yagi K, Suzuki S, Ishii M, Tasaka S, Betsuyaku T, Hasegawa N.

Am J Respir Crit Care Med. 2016 Feb 1;193(3):e5-6. doi: 10.1164/rccm.201508-1527IM. No abstract available.

PMID:
26426678
9.

A case of misdiagnosed cesarean scar pregnancy with a viable birth at 28 weeks.

Nukaga S, Aoki S, Kurasawa K, Takahashi T, Hirahara F.

Case Rep Obstet Gynecol. 2014;2014:375685. doi: 10.1155/2014/375685. Epub 2014 Oct 14.

10.

[Conference: lessons in clinical training. Nursing of aged patients in long-term care].

Nukaga S, Kubota K, Aizawa T, Sato K, Saito M.

Kurinikaru Sutadi. 1984 Feb;5(2):194-201. Japanese. No abstract available.

PMID:
6425571

Supplemental Content

Loading ...
Support Center